Compare GBDC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBDC | LQDA |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2010 | 2018 |
| Metric | GBDC | LQDA |
|---|---|---|
| Price | $12.72 | $40.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.17 | ★ $38.60 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 02-04-2026 | 03-18-2026 |
| Dividend Yield | ★ 12.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $857,084,000.00 | $69,216,000.00 |
| Revenue This Year | N/A | $993.31 |
| Revenue Next Year | N/A | $219.14 |
| P/E Ratio | $10.35 | ★ N/A |
| Revenue Growth | 9.80 | ★ 343.41 |
| 52 Week Low | $12.28 | $11.26 |
| 52 Week High | $16.01 | $46.67 |
| Indicator | GBDC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 49.95 |
| Support Level | $12.36 | $41.34 |
| Resistance Level | $12.98 | $46.67 |
| Average True Range (ATR) | 0.28 | 2.53 |
| MACD | -0.07 | -0.56 |
| Stochastic Oscillator | 28.81 | 17.08 |
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.